|
Variable
|
ADRs of glucocorticoid (N = 339)
|
|---|
|
Yes n (151)
|
No n (188)
|
ρ*
|
|---|
|
Sex (%)
|
|
Female
|
122 (48.2)
|
131 (51.8)
|
0.019
|
|
Male
|
29 (33.7)
|
57 (66.3)
| |
|
Age
|
|
≤ 16
|
135 (56.3)
|
105 (43.7)
|
< 0.001
|
|
> 16 years
|
16 (16.2)
|
83 (83.8)
| |
|
Type of glucocorticoid
|
|
Methylprednisolone
|
3 (12.5)
|
21 (87.5)
|
< 0,001
|
|
Prednisone
|
71 (100)
|
0 (0.0)
| |
|
Prednisone / Methylprednisolone**
|
77 (31.6)
|
167 (68.4)
| |
|
Dose of prednisone (mg/kg/day) ***
|
|
≥ 0,5
|
91 (58.1)
|
65 (41.9)
|
< 0.001
|
|
< 0,5
|
57 (35.8)
|
102 (64.2)
| |
|
Disease
|
|
JIA
|
18 (12.8)
|
123 (87.2)
|
< 0.001
|
|
JSLE
|
120 (82.8)
|
25 (17.2)
| |
|
JDM
|
13 (24.5)
|
40 (75.5)
| |
- N - number of patients treated with GCs, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis
- * Chi Pearson square or Fisher’s exact P < 0.05
- ** Prednisone (oral) / Methyprednisolone (pulse therapy) indicates patients treated with GCs and who presented ADRs during the use of combined oral and pulse therapy. Three patients with ADRs and 21 patients in the group without ADRs did not use GCs orally but used pulse therapy only
- *** The dose of 30 mg/kg/dose of pulse therapy was not considered in the calculation
